News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
124,837 Results
Type
Article (7346)
Company Profile (62)
Press Release (117429)
Section
Business (38484)
Career Advice (89)
Deals (5962)
Drug Delivery (10)
Drug Development (23850)
Employer Resources (12)
FDA (3025)
Job Trends (3591)
News (69254)
Policy (4616)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 BioMidwest Digital (1)
2024 Bio NC Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (2)
2024 Pharm Country Standard (2)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (324)
Adcomms (10)
Allergies (3)
Alliances (11250)
ALS (8)
Alzheimer's disease (131)
Antibody-drug conjugate (ADC) (90)
Approvals (3057)
Artificial intelligence (77)
Autoimmune disease (3)
Automation (1)
Bankruptcy (57)
Best Places to Work (3322)
BIOSECURE Act (1)
Biosimilars (32)
Biotechnology (53)
Bladder cancer (51)
Brain cancer (21)
Breast cancer (179)
Cancer (1443)
Cardiovascular disease (15)
Career advice (76)
Career pathing (3)
CAR-T (65)
Cell therapy (149)
Cervical cancer (12)
Clinical research (19939)
Collaboration (302)
Compensation (88)
Complete response letters (1)
COVID-19 (314)
CRISPR (10)
C-suite (80)
Cystic fibrosis (1)
Data (678)
Decentralized trials (1)
Depression (5)
Diabetes (21)
Diagnostics (1312)
Digital health (3)
Diversity (1)
Diversity, equity & inclusion (5)
Drug discovery (41)
Drug pricing (10)
Drug shortages (1)
Duchenne muscular dystrophy (6)
Earnings (13076)
Editorial (8)
Employer branding (2)
Employer resources (13)
Events (23343)
Executive appointments (212)
FDA (3301)
Featured Employer (10)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (148)
Gene editing (18)
Generative AI (7)
Gene therapy (46)
GLP-1 (101)
Government (466)
Guidances (10)
Healthcare (4069)
Huntington's disease (2)
IgA nephropathy (5)
Immunology and inflammation (28)
Indications (12)
Infectious disease (333)
Inflammatory bowel disease (26)
Inflation Reduction Act (1)
Influenza (5)
Intellectual property (22)
Interviews (11)
IPO (2968)
IRA (7)
Job creations (487)
Job search strategy (70)
Kidney cancer (10)
Labor market (2)
Layoffs (123)
Leadership (2)
Legal (475)
Liver cancer (38)
Lung cancer (241)
Lymphoma (73)
Management (3)
Manufacturing (41)
MASH (5)
Medical device (867)
Medtech (867)
Mergers & acquisitions (3108)
Metabolic disorders (56)
Multiple sclerosis (7)
NASH (1)
Neurodegenerative disease (4)
Neuropsychiatric disorders (1)
Neuroscience (196)
NextGen: Class of 2025 (964)
Non-profit (505)
Northern California (742)
Now hiring (7)
Obesity (30)
Opinion (30)
Ovarian cancer (56)
Pain (5)
Pancreatic cancer (48)
Parkinson's disease (18)
Partnered (1)
Patents (33)
Patient recruitment (29)
Peanut (2)
People (12972)
Pharmaceutical (15)
Pharmacy benefit managers (1)
Phase I (7507)
Phase II (8390)
Phase III (6416)
Pipeline (359)
Podcasts (11)
Policy (15)
Postmarket research (472)
Preclinical (2328)
Press Release (2)
Prostate cancer (66)
Psychedelics (2)
Radiopharmaceuticals (162)
Rare diseases (56)
Real estate (742)
Recruiting (5)
Regulatory (4128)
Reports (8)
Research institute (667)
Resumes & cover letters (11)
RSV (8)
Schizophrenia (14)
Series A (33)
Series B (8)
Service/supplier (1)
Sickle cell disease (17)
Southern California (588)
Special edition (1)
Spinal muscular atrophy (16)
Sponsored (3)
Startups (756)
State (1)
Stomach cancer (10)
Supply chain (6)
The Weekly (11)
United States (5338)
Vaccines (117)
Venture capitalists (13)
Webinars (2)
Weight loss (15)
Women's health (1)
Date
Today (35)
Last 7 days (220)
Last 30 days (738)
Last 365 days (9123)
2025 (2137)
2024 (9507)
2023 (10672)
2022 (13168)
2021 (13249)
2020 (11045)
2019 (8690)
2018 (6401)
2017 (7150)
2016 (6309)
2015 (6996)
2014 (4573)
2013 (3106)
2012 (3355)
2011 (3355)
2010 (3062)
Location
Africa (97)
Alabama (19)
Alaska (1)
Arizona (14)
Arkansas (2)
Asia (10713)
Australia (1434)
California (1519)
Canada (391)
China (245)
Colorado (47)
Connecticut (66)
Delaware (93)
Europe (19649)
Florida (186)
Georgia (8)
Idaho (6)
Illinois (145)
India (7)
Indiana (44)
Iowa (1)
Japan (65)
Kansas (8)
Kentucky (9)
Maine (3)
Maryland (197)
Massachusetts (1288)
Michigan (16)
Minnesota (65)
Missouri (6)
Montana (5)
Nebraska (2)
Nevada (5)
New Hampshire (7)
New Jersey (413)
New Mexico (3)
New York (369)
North Carolina (163)
Northern California (742)
Ohio (41)
Oklahoma (1)
Oregon (5)
Pennsylvania (238)
Rhode Island (4)
South America (114)
South Carolina (2)
Southern California (588)
Tennessee (15)
Texas (257)
Utah (37)
Virginia (15)
Washington D.C. (5)
Washington State (147)
Wisconsin (11)
124,837 Results for "sierra oncology".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain.
June 14, 2024
·
5 min read
Pharm Country
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings.
February 26, 2024
·
6 min read
Drug Development
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European BMT Annual Meeting
Actinium Pharmaceuticals, Inc. announced that results from the Phase 3 SIERRA trial of Iomab-B in patients with a TP53 mutation have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society being held April 14 – 17, 2024, in Glasgow, Scotland.
April 1, 2024
·
5 min read
Press Releases
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
April 1, 2025
·
4 min read
Press Releases
Kura Oncology to Participate in Stifel Targeted Oncology Forum
April 1, 2025
·
2 min read
Press Releases
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 2, 2025
·
1 min read
Cancer
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a crossroads, with experts highlighting novel targets, combinations and pre-emptive immunization as the next wave for IO.
March 3, 2025
·
7 min read
·
Heather McKenzie
Business
Sierra Oncology Reports First Quarter 2022 Results
Sierra Oncology, Inc. today reported its financial and operating results for the first quarter ended March 31, 2022.
May 6, 2022
·
9 min read
Deals
BridgeBio Oncology Takes Unexpected SPAC Track to Public Markets in $450M Deal
In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix Acquisition Corp. II worth $450 million in proceeds.
February 28, 2025
·
2 min read
·
Annalee Armstrong
BioForest
Sierra Oncology to Participate in Guggenheim Oncology Conference
Sierra Oncology, Inc., a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, announced the company will participate in the 4th Annual Guggenheim Oncology Conference being held virtually from February 9 – 11, 2022.
February 3, 2022
·
1 min read
1 of 12,484
Next